Navigation Links
Keryx Biopharmaceuticals Receives Nasdaq Notification
Date:4/25/2008

NEW YORK, April 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Marketplace Rule 4450 (a)(5). This notification, which was received in a letter dated April 22, 2008, is a standard communication when the bid price of a Nasdaq-listed company closes below the minimum $1.00 per share requirement for 30 consecutive business days. The letter states that, in accordance with Marketplace Rule 4450(e)(2), the Company will be provided 180 calendar days to regain compliance by having the bid price of its common stock close at $1.00 per share or more for a minimum of 10 consecutive business days. The letter has no immediate effect on the listing of the Company's common stock at this time.

The Company plans to apply to transfer its listing to the Nasdaq Capital Market. If the Company's application to transfer its listing to the Nasdaq Capital Market is approved and the listing is transferred, the Company will be subject to the continued listing requirements of the Nasdaq Capital Market after such transfer, and no longer subject to the continued listing requirements of the Nasdaq Global Market. The Company's common stock will continue to trade on the Nasdaq Global Market until the transfer application has been reviewed and approved.

The Company currently meets the requirements for listing on the Nasdaq Capital Market, with the exception of the $1.00 minimum closing bid price requirement, although the Company cannot provide assurance that in the future it will continue to meet th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
2. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
3. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
6. Keryx Biopharmaceuticals Announces Additions to Management Team
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
10. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
11. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...a.,Nov.25/PRNewswire/--Formanybusinesses,2009hasbe...estandfastestgrowingnetworkofexpertphysiciansspeci...alhormones has grownthenumberof physiciansinitsn...ndisinprogresstoaddmorephysician-ownedcenters,incl...hepastyear ,BodyLogicMDhasopened13newbioidenticalh...
(Date:11/25/2009)...swire-FirstCall/--ArdeaBiosciences,Inc.(Nasdaq: RD...entandchiefexecutiveofficer,willpresentatthePiperJ...tiondetailsareasfollows:,PiperJaffray21stAnnualHe...e:2:00p.m.EasternTime,Location:TheNewYorkPalaceHot...-ir.net/ireye/,target=,_blank,title=,http://www.c...
(Date:11/24/2009)... New York investment bank KTA Capital,s client Neu...$6.7 mil convertible note private placement with a...t was arranged by KTA Capital as Neuren,s exclusiv... New York (PRWEB) November 23, 2009 -- The ...LLC ("KTA Capital") has announced that i...
(Date:11/24/2009)...swire-FirstCall/--Sigma-AldrichCorporation(Nasdaq:...uesday,December1stat1:45PMGMTinLondon,7:45AMUS/CST...ertheInternetavailableat http://inve s tor.sig ...contoaccessthisfile. ,, AboutSigma-Aldrich: ...ycompany.Itschemicalandbiochemicalproductsandkitsa...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...4 IDS is pleased to announce,that their new, uniq...l EIA,to allow the specific assessment of type I c...ble., The IDS Rat/Mouse P1NP is the first commerc... collagen levels in rodent specimens*. The use,of ...osis drug candidates,in pre-clinical studies and i...
...ERKELEY HEIGHTS, N.J., Jan. 11 Genta,Incorporated... has received,notice from the Listing Qualificatio...on the Company,s non-compliance with the stockhold...place Rule 4450(a)(3), the Company,s,common stock ...ket unless,the Company requests a hearing before a...
...arr Pharmaceuticals,Inc. (NYSE: BRL ) today confi...has initiated a challenge of the patent listed by ...amenda(R) (memantine,hydrochloride) tablets, 5mg a...lication (ANDA) containing a,paragraph IV certific...Food,& Drug Administration (FDA) on October 16, 20...
Other Biology Technology:A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations. 2Genta Receives Notice of Non-Compliance With NASDAQ Rule 2Genta Receives Notice of Non-Compliance With NASDAQ Rule 3Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg 2Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg 3
(Date:11/24/2009)...has long held secrets of the earth,s history locke... been very little information on the environments ...lions of years. Now, a team of researchers from ni...o the tune of $10 million dollars by the National ...f things literally. These scientists will drill t...
(Date:11/23/2009)...unity-associated strain of the deadly superbug MRS...ommon antibioticsposes a far greater health threat...hospitals, according to a study in the December is...w threat is easily picked up in fitness centers, s...the overall burden of MRSA within hospitals, the r...
(Date:11/23/2009)...search suggests that a common oral bacterium may e...by Nichols et al, "Unique Lipids from a Common Hum... Capable of Enhancing Autoimmunity," appears in th...Pathology . , Multiple sclerosis (MS), a disease...nal cord, affects nearly 1 in 700 people in the Un...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2NovoLogix Inc Receives EHNAC Healthcare Network Accreditation 55157 1NovoLogix Inc Receives EHNAC Healthcare Network Accreditation 55157 2NovoLogix Inc Receives EHNAC Healthcare Network Accreditation 55157 3NIAID to fund new human immune profiling research centers 55152 1NIAID to fund new human immune profiling research centers 55152 2Twitter and health care can a tweet a day keep the doctor away 3F 55147 1Twitter and health care can a tweet a day keep the doctor away 3F 55147 2
...t in high tech tools, researchers have identified ...nic lung rejection up to 20 months before the reje...e highest mortality rate of organ recipients, abou...pulmonologist Chris Wendt. Currently, there is no ...l, and when signs of chronic rejection appear, it ...
...the ability of liver cells to interact with T cell...immune response) found that such interactions do o...may take place. The results may help explain the a...other conditions and may be useful in developing t...es. , The results of this study appear in the Nove...
...ore species in the tropics than in the temperate r...ive in the tropics (perhaps more than half), but t.... , Many researchers have hypothesized that clima...e quickly in tropical regions. In a paper appearin..., John Wiens and a group of researchers from Stony...
Other Biology News:Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3Interaction between lymph and liver cells may affect immune response 2Interaction between lymph and liver cells may affect immune response 3More species in the tropics because species have been there longer 2
FliTrx Panning Kit from Invitrogen
...ludes: Sufficient library for 10 separate biopanni...equences, -28 gIII Sequencing Primer (100 pmol), f...er (100 pmol), for automated DNA sequencing, Host ...n) and Elutant (Biotin), Detailed protocols for su...
...ntigen and antibody-based immunoaffinity matrices,...ny times without compromising antigen-antibody rea...gents has precluded the application of these metho... Western Blot Mild Antibody Stripping Solution con...
...0 Series of positioning slides offers multiple dri... leadscrew, micrometer, and manual. With this seri...ective multi-axis systems. These slides also offer...solutions down to 10 nanometers, integrated home/ ...
Biology Products: